The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained widespread acceptance in clinical practice and are increasingly assuming a more pivotal role in diabetes care. Knowledge pertaining to GLP-1 RAs is quickly amassing as clinical experience with these agents continues to grow. Accordingly, endocrinologists and other endocrinology professionals need to be aware of the latest advances and their potential impact on future GLP-1 RA applications.
This activity was derived from content presented during the live symposium at ENDO 2013. Audio recordings of faculty commentary are used here to enhance the clinical data and reinforce key discussion points.